Drug Search Results
More Filters [+]

Fluvastatin

Alternative Names: fluvastatin, lescol xl, lescol
Latest Update: 2024-12-11
Latest Update Note: Clinical Trial Update

Product Description

Fluvastatin is a commonly used cholesterol lowering agent (statin) that is associated with mild, asymptomatic and self-limited serum aminotransferase elevations during therapy and rarely with clinically apparent acute liver injury. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Fluvastatin)

Mechanisms of Action: HMG-CoA Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | Finland | France | Germany | Greece | Hungary | India | Ireland | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: Atherosclerosis | Dyslipidemia | Hypercholesterolemia

Known Adverse Events: Abdominal Pain | Headache | Pain Unspecified | Myalgia | Dyspepsia

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Fluvastatin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events